Moleculin BiotechMBRX
13F holders, Q3 2025 (September 30)25holders +3
8new positions
5sold out
$0.53avg. 13F price*
At the end of Q3 2025, 25 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings, up 3 from Q2 2025. 8 opened new positions and 5 sold out. The largest holders were Vanguard Group Inc. ($127K), Geode Capital Management, LLC ($110K) and HRT Financial LP ($61K).
- Company
- Moleculin Biotech Inc.
- CUSIP
- 60855D309
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $116K |
| Exits | 5 | $67K |
All 13F filers, Q2 2025 → Q3 2025: 615,102 shares bought and 226,481 shares sold, net +388,621 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 25 holders
| Vanguard Group Inc. | 0.00% | Add +675.6% | 239,919 | $127K |
| Geode Capital Management, LLC | 0.00% | Add +656.3% | 208,210 | $110K |
| HRT Financial LP | 0.00% | New | 115,190 | $61K |
| LPL Financial LLC | 0.00% | Add +3.6% | 58,080 | $31K |
| Ieq Capital, LLC | 0.00% | New | 36,363 | $19K |
| Wealth Dimensions Group, Ltd. | 0.00% | New | 20,000 | $11K |
| Rockefeller Capital Management L.P. | 0.00% | New | 14,506 | $8K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 12,781 | $7K |
| Goldman Sachs Group Inc. | 0.00% | New | 12,752 | $7K |
| BlackRock, Inc. | 0.00% | No change | 12,380 | $7K |
| Truist Financial Corp. | 0.00% | No change | 10,500 | $6K |
| Ethos Financial Group, LLC | 0.00% | New | 10,034 | $5K |
| Moors & Cabot, Inc. | 0.00% | New | 10,000 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +113.7% | 8,380 | $4K |
| UBS Group AG | 0.00% | Reduce -50.4% | 3,965 | $2K |
| NFSG Corp | 0.00% | No change | 2,867 | $2K |
| Morgan Stanley | 0.00% | No change | 926 | $491 |
| SBI Securities Co., Ltd. | 0.00% | No change | 746 | $395 |
| Bogart Wealth, LLC | 0.00% | No change | 300 | $159 |
| Bank of America Corp. | 0.00% | Add +82.2% | 266 | $141 |
| Osaic Holdings, Inc. | 0.00% | No change | 43 | $20 |
| CVA Family Office, LLC | 0.00% | No change | 34 | $18 |
| North Star Investment Management Corp. | 0.00% | No change | 17 | $9 |
| Lanark Financial, Inc. | 0.00% | New | 14 | $7 |
| Royal Bank of Canada | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.